You are here: Industry Insights > AstraZeneca

News List

AstraZeneca resumes US phase III COVID-19 vaccine trial pharmatimes
October 29, 2020
AstraZeneca has resumed all clinical trials of its coronavirus vaccine candidate after the Food and Drug Administration (FDA) authorised the restart in the US.
AstraZeneca gets FDA approval to restart Phase III Covid-19 vaccine trial pharmaceutical-technology
October 28, 2020
The US Food and Drug Administration (FDA) has authorised the restart of Phase III clinical trial of AstraZeneca and Oxford University’s Covid-19 vaccine candidate, AZD1222, in the country.
AZ presents new real-world chronic kidney disease data at ASN 2020 pharmatimes
October 28, 2020
AstraZeneca presented new findings from the DISCOVER Chronic Kidney Disease (CKD) study at the American Society of Nephrologists (ASN) Kidney Week 2020 Congress last week.
Oxford COVID-19 vaccine trials produce robust immune response in elderly: FT expresspharma
October 27, 2020
The COVID-19 vaccine being developed by the University of Oxford and AstraZeneca produces a robust immune response in elderly people, the Financial Times said on Monday, citing early results.
Peru refuses Covid-19 vaccine purchase deal with AstraZeneca pharmaceutical-technology
October 26, 2020
The Peruvian government has refused to sign an agreement with AstraZeneca to purchase coronavirus vaccine as the latter failed to provide sufficient data from its studies.
AstraZeneca, U.S. Govt. Enter $486M COVID-19 Antibody Agreement contractpharma
October 22, 2020
Funding will be used for two Phase III trials and related development and manufacturing activities for the supply of AZD7442 doses in the U.S.
Brazil volunteer in AstraZeneca COVID-19 vaccine trial dies, trial to go on expresspharma
October 22, 2020
Sources say that the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine, suggesting the person was part of the control group that was given a meningitis jab.
AZ’s Tagrisso scores priority review from FDA pharmatimes
October 22, 2020
AstraZeneca’s EGFR-tyrosine kinase inhibitor Tagrisso has been granted a priority review by the US Food and Drug Administration (FDA) for the treatment of early-stage EGFR-mutated lung cancer.
CHMP recommends AstraZeneca’s Forxiga for approval in EU pharmaceutical-technology
October 21, 2020
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended AstraZeneca’s Forxiga (dapagliflozin) for an indication extension of its marketing authorisation in the European Union (EU).
J&J COVID-19 vaccine trial paused due to unexplained illness in participant expresspharma
October 15, 2020
The participant's illness is being reviewed and evaluated by an independent data and safety monitoring board, as well as the company's clinical and safety physicians, informed J&J.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page